Connect with us

Technology

BIO 2024 Sets the Stage for Taiwan’s Biotech Industry to Shine

Published

on

SAN DIEGO, May 30, 2024 /PRNewswire/ — The 2024 edition of BIO International Convention 2024 (BIO), the world’s largest and most comprehensive global biotech event, will be held from June 3 to 6 at San Diego Convention Center, San Diego, California. Taiwan has been an active participant in the event since 2002, presenting the technological excellence and business opportunities of Taiwan’s biotech industry internationally over the years. Following the success of previous editions, the Biotechnology and Pharmaceutical Industries Promotion Office (BPIPO) will continue to participate in BIO 2024 by organizing a Taiwan delegation.

Along with BPIPO, which is responsible for the coordination and organization of the delegation, the group includes government representatives and legal entities such as the Ministry of Economic Affairs, the Ministry of Agriculture, the Ministry of Health and Welfare, the National Science and Technology Council, the National Development Council, the Academia Sinica, the Industrial Technology Research Institute, the Development Center for Biotechnology and Taiwan Bio Industry Organization, the Taiwan External Trade Development Council and Taipei City Government, together with over 60 delegates and multiple accompanying companies and organizations. On the one hand, the delegation aims to present the innovative landscape of Taiwan’s biotech and healthcare industry and bring cutting-edge technologies and products to the international arena, and on the other hand, it also strives to pursue technological or commercial partnerships that will help Taiwan’s biotech companies to expand their business operations both regionally and globally.

Related article: Taiwan’s Biotech Brilliance Shines at BIO 2023: Unveiling Cutting-Edge Discoveries and Strategic Partnerships

Diverse Advantages that Promote Biotech and Healthcare Development

As the center of the Asia-Pacific (APAC) region, Taiwan serves as an essential hub connecting Europe, the United States, Japan, and other emerging markets in the region. Various surveys have shown that Taiwan ranks among the world’s leaders in economic freedom, digital competitiveness, and global competitiveness, making it one of the most attractive locations for multinational corporations and investors to establish branches or even regional headquarters.

In terms of medical services, Taiwan has one of the world’s leading healthcare and health insurance systems, providing high-quality, accessible, and affordable care to the public. According to the Health Care Index announced in February 2024 by Numbeo, a global database website, Taiwan has been ranked first in the world for five consecutive years. 

With the vision of “Health for All Ages 2030,” the Taiwanese government is committed to promoting the development of regenerative medicine and precision medicine, encouraging corporate investment in biotechnology, as well as pursuing cross-sector collaborations and international exchanges. Remarkably, with its world leadership in the ICT industry and abundant R&D capacity, Taiwan provides an excellent platform for advancing medical technologies, such as digital medicine, AI-assisted drug discovery, and medical AI.

Meanwhile, Taiwan has established several comprehensive bioclusters in the northern, central, and southern regions, covering various areas including drug discovery, small molecules and biologics manufacturing, medical devices, in-vitro diagnostics, agricultural biotechnology, and health supplements. Moreover, Taiwan is gradually developing a reliable clinical trial environment and robust trial capacity thanks to its well-established medical centers and hospitals. These strengths, together with Taiwan’s strong regulatory compatibility and intellectual property protection, enable Taiwan to create a more integrated ecosystem for the life sciences industry, thereby making it the “best partner in Asia“, a prime destination for global biotech market players.

Taiwan Pavilion as a Stage for Taiwan’s Biotech Industry to Shine in BIO 2024

Under the theme of “Time for Science to Shine,” BIO 2024 is anticipated as an exciting gathering of over 20,000 industry elites, researchers, healthcare professionals, and investors across the globe. The Taiwan delegation is looking forward to showcasing Taiwan’s diverse advantages to all participants and helping Taiwan’s biotech and healthcare industries shine in the international arena through this grand event.

Carrying forward the proven success of previous years, the Taiwan delegation will continue to set up the Taiwan Pavilion at BIO 2024 this year. Delegates encompass a wide range of cutting-edge fields such as biotechnology (including agricultural biotechnology), new drug discovery (including small molecule drugs and biologics), precision health, medical devices, smart health, and CDMO, along with multiple governmental, academic, research, and medical organizations and industry associations, jointly demonstrating Taiwan’s achievements in the cooperation between the industry, government, academia, research, and healthcare sectors.

During the 4-day event, the delegates will showcase their innovative technologies and solutions in the Taiwan Pavilion. They can also leverage this unique platform to engage in one-on-one business partnering sessions, seeking to establish links with leading international companies and investors, building an international R&D collaboration network, and boosting Taiwan’s presence in the global biotech community.

As an opportunity to promote networking and interactions between the delegates and global biomedical professionals, BPIPO also welcomes all prospective collaborators and investors to visit the Taiwan Pavilion located at Booths 1817 and 1917 and join the Opening Ceremony and Happy Hour on June 3, 2024, 16:30-17:30.

Related article:
2023 Precision Medicine Industry Policy White Paper Paves the Way for Biotechnology in Taiwan 

View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-2024-sets-the-stage-for-taiwans-biotech-industry-to-shine-302159251.html

SOURCE The Biotechnology and Pharmaceutical Industries Promotion Office (BPIPO)

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

CreateAI Announces Results of 2024 Annual Meeting of Stockholders

Published

on

By

SAN DIEGO, Dec. 23, 2024 /PRNewswire/ — CreateAI Holdings Inc., formerly TuSimple Holdings Inc. (OTCMKTS: TSPH) (“CreateAI” or the “Company”), a global artificial intelligence technology company, today announced shareholder voting results for its annual meeting of stockholders held on December 20, 2024 (the “Annual Meeting”).

As of October 28, 2024, the record date for the Annual Meeting, there were a total of 232,618,399 shares of common stock outstanding and entitled to vote at the Annual Meeting, comprised of 208,618,399 shares of Class A Common Stock (each with one vote per share) and 24,000,000 shares of Class B Common Stock (each with ten votes per share). At the Annual Meeting, holders of 207,347,538 shares of common stock, representing 423,347,538 votes, entitled to vote at the meeting were represented in person or by proxy and, therefore, a quorum constituted of the majority of the voting power of the shares of common stock issued and outstanding and entitled to vote at the Annual Meeting was present.

The following is a brief description of each matter voted upon at the 2024 Annual Meeting and the numbers of votes cast for, withheld, or against, the number of abstentions, and the number of broker non-votes with respect to each other, as applicable.

1.     Election of six nominees to serve on the Board of Directors (the “Board”) for a term which will expire at the 2025 annual meeting of stockholders, or, if Proposal Two is adopted, to hold office until the annual meeting of stockholders in accordance with the class of director to which each nominee will be assigned. The following six directors were elected by the votes as indicated below.

 
 

For

 

Withheld

 

Broker Non-Votes

Cheng Lu

 

208,949,915

 

164,765,0191

 

49,632,604

Mo Chen

 

208,946,146

 

164,768,7881

 

49,632,604

James Lu

 

209,109,928

 

164,605,0061

 

49,632,604

Zhen Tao

 

209,158,316

 

164,556,6181

 

49,632,604

Albert Schultz

 

348,895,0191

 

24,819,915

 

49,632,604

Jianan Hao

 

209,021,652

 

164,693,2821

 

49,632,604

The totals above include the 240,000,000 votes represented by the Class B shares of Common Stock. 12,000,000 shares of Class B Common Stock (representing 120,000,00 votes) were voted “FOR” and 12,000,000 shares of Class B Common stock (representing 120,000,00 votes) were voted “WITHHELD” for each of the Directors other than Albert Schultz. All shares of Class B Common Stock were voted “FOR” the election of Albert Schultz. Excluding the 240,000,000 votes from the 24,000,000 shares of Class B Common Stock from the totals above, the 183,347,538 shares of Class A Common Stock were voted as indicated below.

 
 

For

 

Withheld

 

Broker Non-Votes

Cheng Lu

 

88,949,915

 

44,765,019

 

49,632,604

Mo Chen

 

88,946,146

 

44,768,788

 

49,632,604

James Lu

 

89,109,928

 

44,605,006

 

49,632,604

Zhen Tao

 

89,158,316

 

44,556,618

 

49,632,604

Albert Schultz

 

108,895,019

 

24,819,915

 

49,632,604

Jianan Hao

 

89,021,652

 

44,693,282

 

49,632,604

2.       Amendment to the Company’s Restated Certificate of Incorporation to classify the Board of Directors into three classes, with directors in each class to serve staggered three-year terms. Pursuant to the Restated Certificate of Incorporation, Proposal Two must receive the affirmative vote of the holders of at least a majority of the voting power of all of the then-outstanding shares of the capital stock of the Company entitled to vote generally in the election of directors, voting together as a single class, since directors representing two-thirds (2/3) of the total number of authorized directors have already approved. The amendment was not approved2 by the votes as indicated below:

For

 

Against1

 

Abstain

 

Broker Non-Votes

208,955,668

 

164,659,652

 

99,614

 

49,632,604

Because Proposal Two was not approved, the six directors elected pursuant to Proposal One will serve on the Board for a term which will expire at the 2025 annual meeting of stockholders.

3.       Ratification of the appointment of UHY LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024. The selection was ratified by the votes as indicated below:

For

 

Against1

 

Abstain

 

Broker Non-Votes

255,504,371

 

155,923,768

 

11,919,399

 

Note 1: Includes 120,000,000 votes of the 12,000,000 shares of Class B Common Stock held by White Marble LLC and White Marble International Limited (together, the “White Marble Entities”) controlled by Dr. Xiaodi Hou.

Note 2: The White Marble Entities have filed an action in the Delaware Court of Chancery seeking a declaratory judgment that the voting agreement between White Marble and Mo Chen is invalid and White Marble, not Mo Chen, controls the vote. White Marble LLC v. Chen, C.A. No. 2024-1208-PAF (Del. Ch.) On December 13, 2024, the Court entered an order that allows the Company to hold the vote on Proposal Two, and ordered that if Proposal Two is not approved at the Annual Meeting but the Court determines in the Action that Mo Chen, not the White Marble Entities, control how the White Marble Entities’ Shares are voted, then the White Marble Entities’ shares shall be deemed to have been voted in favor of Proposal Two at the Annual Meeting and that such vote shall stand. The vote totals above include the votes of the shares held by the White Marble Entities as voted by the White Marble Entities. If the shares held by the White Marble entities reflected in the totals above are deemed to have been voted in favor of Proposal Two, the Proposal will have passed. Accordingly, if the Court rules in Mo Chen’s favor, Proposal Two will be deemed to have passed and the Company would be permitted to amend its Certificate of Incorporation to implement Proposal Two and each of the directors elected pursuant to Proposal One will serve on the Board until the annual meeting of stockholders in accordance with the class of director to which each nominee is assigned.

About CreateAI

CreateAI (formerly TuSimple) is a global artificial intelligence company with offices in US, China, and Japan. The company is pioneering the future of digital entertainment content production, seamlessly blending cutting-edge generative AI technology with the creativity of world-class talent. Our mission is to redefine the boundaries of what’s possible in digital storytelling by developing immersive, captivating, and visually stunning experiences that resonate with audiences on a global scale.

Investor Relations Contact:
ICR for CreateAI
CreateAI.IR@icrinc.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/createai-announces-results-of-2024-annual-meeting-of-stockholders-302338618.html

SOURCE CreateAI Holdings Inc

Continue Reading

Technology

Rosica Communications Releases V2 of Thought Leadership Measurement Matrix™

Published

on

By

Beta Phase Concludes, Formerly Launching Market Influence Platform

FAIR LAWN, N.J., Dec. 23, 2024 /PRNewswire-PRWeb/ — Rosica Communications, a national PR agency specializing in education, animal health, nonprofits, and healthcare, has completed beta-testing of its comprehensive tool for assessing thought leadership, now called the Thought Leadership Measurement Matrix™. This innovative tool utilizes a unique, weighted algorithm to measure and analyze 20 marketing, online, and public relations factors or activities that impact thought leadership and influence industry reputation and standing.

“Rosica goes beyond traditional web metrics to deliver a tool that tracks the broader scope of an organization’s thought leadership activities.”

This PR thought leadership measurement system provides both qualitative and quantitative assessments of an organization’s market influence, pinpointing strengths and uncovering opportunities for advancing thought leadership. After nearly two years of development and retaining an analytics specialist and mathematician in 2024 to advance its thought leadership scoring tables, Rosica’s Thought Leadership Measurement Matrix™ is now ready for prime time. Formerly launched by Rosica as the “Thought Leadership Index,” this is the only tool that thoroughly measures 20 distinct variables affecting thought leadership. It allows organizations to gauge their leadership presence through an in-depth analysis of performance indicators, SEO, content marketing (owned media), speaking engagements, website traffic and user experience (UX), and influencer or KOL advocacy.

“Completing the beta phase with our clients created insights that shaped the final PR and thought leadership measurement platform we’re now officially introducing. The Thought Leadership Measurement Matrix™ is the most comprehensive tool available to measure earned, owned, social, and paid media, plus a number of additional online and traditional marketing, PR, and communications activities that move the needle for organizations to impact of their thought leadership,” said Chris Rosica, CEO and president of Rosica Communications.

“Rosica goes beyond traditional web metrics to deliver a tool that tracks the broader scope of an organization’s thought leadership activities. This tool doesn’t just measure visibility, it quantifies influence, helping organizations not only get noticed but also become recognized leaders in their industries,” said Analytics Specialist Dan Scheuermann.

For more information, visit http://www.rosica.com

Media Contact

Micah Carroll, Rosica Communications, 201-843-5600, micah@rosica.com, www.Rosica.com

View original content to download multimedia:https://www.prweb.com/releases/rosica-communications-releases-v2-of-thought-leadership-measurement-matrix-302338568.html

SOURCE Rosica Communications

Continue Reading

Technology

KORE Announces NYSE Acceptance of Plan to Regain Listing Compliance

Published

on

By

ATLANTA, Dec. 23, 2024 /PRNewswire/ — KORE Group Holdings, Inc. (NYSE: KORE) (“KORE” or the “Company”), the global pure-play Internet of Things (“IoT”) hyperscaler and provider of IoT Connectivity, Solutions, and Analytics, today announced it has received notification (the “Acceptance Letter”) from the New York Stock Exchange (the “NYSE”) that the NYSE has accepted the Company’s previously-submitted plan (the “Plan”) to regain compliance with the NYSE’s continued listing standards set forth in Section 802.01B of the NYSE Listed Company Manual relating to minimum market capitalization and stockholders’ equity. In the Acceptance Letter, the NYSE granted the Company an 18-month period from September 12, 2024 (the “Plan Period”) to regain compliance with the continued listing standards. As part of the Plan, the Company is required to provide the NYSE quarterly updates regarding its progress towards the goals and initiatives in the Plan. In the Plan, Kore included details regarding previously reported operational restructuring activities, as well as an outlook on the Company’s business. 

The Company expects its common stock will continue to be listed on the NYSE during the Plan Period, subject to the Company adherence to the Plan and compliance with other applicable NYSE continued listing standards. The Company’s receipt of such notification from the NYSE does not affect the Company’s business, operations or reporting requirements with the U.S. Securities and Exchange Commission.

Cautionary Note on Forward-Looking Statements

This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “believe,” “guidance,” “project,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook,” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding expected progress with the Company’s compliance plan submitted to the NYSE, expected compliance with continued listing standards of the NYSE and expected continued listing of the Company’s common stock on the NYSE. These statements are based on various assumptions and on the current expectations of KORE’s management. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on by any investor or other person as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of KORE. These forward-looking statements are subject to a number of risks and uncertainties, including general economic, financial, legal, political and business conditions and changes in domestic and foreign markets; the potential effects of COVID-19; risks related to the rollout of KORE’s business and the timing of expected business milestones; risks relating to the integration of KORE’s acquired companies, including the acquisition of Twilio’s IoT business, changes in the assumptions underlying KORE’s expectations regarding its future business; our ability to negotiate and sign a definitive contract with a customer in our sales funnel; our ability to realize some or all of estimates relating to customer contracts as revenue, including any contractual options available to customers or contractual periods that are subject to termination for convenience provisions; the effects of competition on KORE’s future business; and the outcome of judicial proceedings to which KORE is, or may become a party. If the risks materialize or assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that KORE presently does not know or that KORE currently believes are immaterial that could also cause actual results to differ materially from those contained in the forward-looking statements. In addition, forward-looking statements reflect KORE’s expectations, plans or forecasts of future events and views as of the date of this press release. KORE anticipates that subsequent events and developments will cause these assessments to change. However, while KORE may elect to update these forward-looking statements at some point in the future, KORE specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing KORE’s assessments as of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.

KORE Investor Contact:

Vik Vijayvergiya
Vice President, IR, Corporate Development and Strategy
vvijayvergiya@korewireless.com
(770) 280-0324

View original content to download multimedia:https://www.prnewswire.com/news-releases/kore-announces-nyse-acceptance-of-plan-to-regain-listing-compliance-302338621.html

SOURCE KORE Group Holdings, Inc.

Continue Reading

Trending